GB201506663D0 - In-vivo delivery of ion chelating ligands for therapy - Google Patents

In-vivo delivery of ion chelating ligands for therapy

Info

Publication number
GB201506663D0
GB201506663D0 GBGB1506663.2A GB201506663A GB201506663D0 GB 201506663 D0 GB201506663 D0 GB 201506663D0 GB 201506663 A GB201506663 A GB 201506663A GB 201506663 D0 GB201506663 D0 GB 201506663D0
Authority
GB
United Kingdom
Prior art keywords
therapy
vivo delivery
ion chelating
chelating ligands
ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1506663.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KOMPLEXIS Srl
Original Assignee
KOMPLEXIS Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KOMPLEXIS Srl filed Critical KOMPLEXIS Srl
Priority to GBGB1506663.2A priority Critical patent/GB201506663D0/en
Publication of GB201506663D0 publication Critical patent/GB201506663D0/en
Priority to PCT/EP2016/058811 priority patent/WO2016170015A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B15/00—Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
    • C08B15/005—Crosslinking of cellulose derivatives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08—Cellulose derivatives
    • C08L1/26—Cellulose ethers
    • C08L1/28—Alkyl ethers
    • C08L1/286—Alkyl ethers substituted with acid radicals, e.g. carboxymethyl cellulose [CMC]
GBGB1506663.2A 2015-04-20 2015-04-20 In-vivo delivery of ion chelating ligands for therapy Ceased GB201506663D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1506663.2A GB201506663D0 (en) 2015-04-20 2015-04-20 In-vivo delivery of ion chelating ligands for therapy
PCT/EP2016/058811 WO2016170015A1 (en) 2015-04-20 2016-04-20 Epoxy derivatives of ion chelating ligands, their polymeric conjugates and medical uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1506663.2A GB201506663D0 (en) 2015-04-20 2015-04-20 In-vivo delivery of ion chelating ligands for therapy

Publications (1)

Publication Number Publication Date
GB201506663D0 true GB201506663D0 (en) 2015-06-03

Family

ID=53298845

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1506663.2A Ceased GB201506663D0 (en) 2015-04-20 2015-04-20 In-vivo delivery of ion chelating ligands for therapy

Country Status (2)

Country Link
GB (1) GB201506663D0 (en)
WO (1) WO2016170015A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115260401B (en) * 2022-07-29 2023-11-03 天津绿菱气体有限公司 Chelate resin for capturing electronic grade hexafluorobutadiene metal ions and preparation method thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5915325B2 (en) * 1981-03-26 1984-04-09 工業技術院長 Method for producing polyolefin film or fiber with crown ether ring
JPS5915323B2 (en) * 1981-08-28 1984-04-09 工業技術院長 Method for producing alkali metal trap material
DE3644346A1 (en) * 1986-12-19 1987-05-21 Saeulentechnik Dr Ing Herbert Matrix-bound crown ether ligands as separating material in the affinity chromatography of nucleic acids
DK169306B1 (en) * 1989-06-14 1994-10-10 Af 18 Juni 1990 As Means for removing or inactivating unwanted components in blood or other extracellular body fluids and method of preparing dextran-O-carbonyl-benzo-18-crown-6 and of dextran-hydroxyethylbenzo-18-crown-6
US20050013925A1 (en) * 2003-07-17 2005-01-20 Melvin Cabey Immobilization methods for organic molecules telomers and polymers on solid substrates
US7390863B2 (en) * 2005-08-30 2008-06-24 Bausch & Lomb Incorporated Polymeric materials having enhanced ion and water transport property and medical devices comprising same
US8802074B2 (en) * 2008-11-26 2014-08-12 Board Of Regents, The University Of Texas System Polymers functionalized with ion-specific recognition elements

Also Published As

Publication number Publication date
WO2016170015A1 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
IL254705B (en) Combination therapy for cancer
ZA201802420B (en) Combination therapy for treating malignancies
IL255060A0 (en) Combination therapy for treating cancer
ZA201803166B (en) Combination therapy for treating malignancies
HK1252425A1 (en) Triazoles for the treatment of demyelinating diseases
HK1254882A1 (en) Combination therapies for treatment of cancer
ZA201802088B (en) Combination therapy for treating malignancies
IL258684A (en) Combination therapy for treating malignancies
IL253461A0 (en) Hydrogels for delivery of therapeutic compounds
GB2534986B (en) Inhaler housing
HK1258128A1 (en) Selection of patients for combination therapy
GB201506663D0 (en) In-vivo delivery of ion chelating ligands for therapy
HK1254687A1 (en) Combination therapy for cancer
HRP20210383T8 (en) Combination therapy for cancer
HK1259026A1 (en) Localized delivery of anti-fugetactic agent for treatment of cancer
SG11201801083UA (en) Tumor therapeutic agent
GB201518805D0 (en) Therapy
GB201506944D0 (en) Therapeutic treatment
GB201511120D0 (en) Cancer therapy
GB201511121D0 (en) Cancer therapy
GB201417819D0 (en) Agents for cancer therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)